Clinical trial · Interventional
Sentinel Lymph Node Biopsy With Hybrid Technique in Breast Cancer
The Comparative Analysis of Multimodal Markers to Identify Sentinel Lymph Node in Breast Cancer
NCT04274946CI-TRIAL-00043500unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Sentinel lymph node (SLN) biopsy is the gold standard method to stage axilla in breast cancer. The aim of the study is to compare the efficiency of various methods to identify SLN is breast cancer patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Sentinel lymph node biopsy | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- type
- ACTIVE_COMPARATOR
- label
- RAI+PB+US
- description
- Sentinel lymph node mapping with dual tracer (radioisotope and patent blue) and intraoperative ultrasound to identify SLN in the breast cancer patients
- interventionNames
- Procedure: Sentinel lymph node biopsy
- type
- EXPERIMENTAL
- label
- RAI+ICG+US
- description
- Sentinel lymph node mapping with dual tracer (radioisotope and ICG) and intraoperative ultrasound to identify SLN in the breast cancer patients
- interventionNames
- Procedure: Sentinel lymph node biopsy
- type
- EXPERIMENTAL
- label
- RAI+PB+ICG+US
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically confirmed primary breast cancer by core needle, incisional or excisional biopsy * cN0 patients * In patients with abnormal axillary lymph nodes sonographically US-guided FNA cytology of these nodes were performed and FNA cytology negative patients planed to undergo SLNB with different mapping techniques. Exclusion Criteria: * Patients with neoadjuvant therapy * Patients with pathological diagnosed ductal carcinoma in situ by excisional biopsy * Patients with pathologically proven axillary disease * Patients with T4d tumor
References
Publications (0)
Data not yet available
No reference posted for this study.